Drug Trial Radar · NCT03580356
A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
Last checked: Nov 20, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,078
Actual
Start
Oct 20, 2018
Primary completion
Jun 22, 2021
Study completion Jun 14, 2022
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remained symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab and over placebo. The study population consisted of 1,079 male and female subjects aged ≥ 12 years who were diagnosed with CSU and who remained symptomatic despite the use of H1-antihistamines. This was a multi-center, randomized, double-blind, active- and placebo-controlled, parallel-group study. There was a screening period of up to 28 days, a 52 week double-blind treatment period, and a 12 week post-treatment follow-up period.
Conditions
- Chronic Spontaneous Urticaria
Interventions
LigelizumabBiological
Liquid in vial
OmalizumabBiological
Lyophilized powder for solution in vial
PlaceboOther
Liquid in vial
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in UAS7 at Week 12 (Multiple Imputation) of Adult SubjectsTime frame: Baseline, Week 12
- Mean Change From Baseline in UAS7 at Week 12 (Observed Data) of Adolescent Subjects (FAS)Time frame: Baseline, Week 12
Locations
183 sites in 27 countries. Site status is shown where the registry gives one.
Allervie Clinical Research
Birmingham, Alabama
Medical Resch of Arizona-Div of Allergy Asthma and Immunology
Scottsdale, Arizona
Atria Clinical Research Asthma and Allergy Institute
Little Rock, Arkansas
DeMera Allergy Asthma and Immun Ctr
Fresno, California
California Allergy and Asthma Medical Group
Los Angeles, California
Jonathan Corren Inc
Los Angeles, California
Allergy and Asthma Consultants
Redwood City, California
Allergy and Asthma Associates of Santa Clara Vally Center
San Jose, California
Sarasota Clinical Research
Sarasota, Florida
Olympian Clinical Research
Tampa, Florida
Idaho Research
Eagle, Idaho
Midwest Allergy Sinus Asthma SC
Normal, Illinois
John Hopkins University
Baltimore, Maryland
Institute for Asthma and Allergy PC
Chevy Chase, Maryland
Chesapeake Clinical Research
White Marsh, Maryland
Mayo Clinic Rochester
Rochester, Minnesota
Midwest Clinical Research LcLC
St Louis, Missouri
Montana Medical Research
Missoula, Montana
The Asthma and Allergy Center PC
Papillion, Nebraska
Icahn School Of Med At Mount Sinai
New York, New York
Toledo Institute of Clinical Research
Toledo, Ohio
Allergy Asthma and Clinical Research
Oklahoma City, Oklahoma
PCR DBA Columbia Asthma and Allergy
Clackamas, Oregon
Allergy and Asthma Specialists PC
Blue Bell, Pennsylvania
Allergy and Clinical Immunology Associates
Pittsburgh, Pennsylvania
National Allergy and Asthma Research LLS
North Charleston, South Carolina
Bellaire Dermatology Associates
Bellaire, Texas
Western Sky Medical Research
El Paso, Texas
North Texas Inst For Clinical Tri
Fort Worth, Texas
Allergy and Asthma Research Center PA
San Antonio, Texas
Quality Assurance Research Center
San Antonio, Texas
Allergy and Asthma Care of Waco
Waco, Texas
Allergy Associates of Utah
Sandy City, Utah
Bellingham Asthma Allergy and Immunology
Bellingham, Washington
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
Salta, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Mendoza, Mendoza Province, Argentina
Showing 40 of 183 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.